To the best of our knowledge, this is the first study specifically assessing the effect of SGLT2 inhibitors on cardiovascular risk stratification using the SCORE2-DM model in patients with Type 2 diabetes mellitus. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.